We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Human Genome Sciences (HGS) has announced interim week-12 results of a Phase IIb clinical trial of Albuferon (albinterferon alfa-2b) in combination with ribavirin in patients with genotype 1 chronic hepatitis C virus infection who are naive to interferon alpha-based treatment regimens.
Emisphere Technologies announced that Novartis and its development partner Nordic Bioscience have begun a Phase III clinical trial of an oral form of salmon calcitonin, which uses Emisphere's eligen delivery technology, for the treatment of osteoporosis.
GlaxoSmithKline (GSK) has presented data showing that that fluticasone furoate nasal spray (FFNS), a once-a-day allergy medicine under FDA review, effectively treats sneezing, runny nose, nasal itching and nasal congestion in children 2 to 11 years old with seasonal and year-round nasal allergies.
Mylan Laboratories announced that Mylan Pharmaceuticals has received tentative approval from the FDA for its abbreviated new drug application (ANDA) for ondansetron orally disintegrating tablets, 4 and 8 mg.
Taro Pharmaceutical Industries announced it has received tentative approval from the FDA for its abbreviated new drug application (ANDA) for ranitidine syrup, 15 mg/mL.
Hollis-Eden Pharmaceuticals has reported study results demonstrating that its acute radiation syndrome drug candidate, Neumune (HE2100), significantly improved survival in clinically unsupported rhesus monkeys with radiation-induced myelosuppression.
LifeCycle Pharma has announced positive results from its Phase I clinical program with LCP-AtorFen, a fixed-dose combination product of atorvastatin and fenofibrate for the treatment of high cholesterol levels.
Cell Therapeutics has announced preliminary results from an investigator-sponsored Phase II study of Xyotax (paclitaxel poliglumex) in patients with androgen-independent prostate cancer, the majority of whom had failed prior treatment with taxane chemotherapy.